株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

EpiCast Report:世界の大腸癌の疫学的予測

EpiCast Report: Colorectal Cancer - Epidemiology Forecast to 2023

発行 GlobalData 商品コード 258691
出版日 ページ情報 英文 54 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
EpiCast Report:世界の大腸癌の疫学的予測 EpiCast Report: Colorectal Cancer - Epidemiology Forecast to 2023
出版日: 2014年12月01日 ページ情報: 英文 54 Pages
概要

大腸癌は男性では3番目、女性では2番目に発症率の高い癌の種類です。そして世界各国で発症率・有病率とも増加傾向にあります。主要9ヶ国全体での発症件数は2012年の123万件から、2022年には175万件へ、年間4.22%もの速度で増加すると予測されています。市場は年齢構成・男女差・癌の診断ステージ・検診計画などで差がありますが、どの市場でも患部の除去が最も一般的な治療法であり、患者の70〜90%が除去手術を受けています。

当レポートでは、世界の主要9ヶ国における大腸がんの罹患状況と今後の見通しについて分析し、大腸癌の特徴や、各国での状況、今後10年間の発症率・有病率の予測値などを調査・推計して、その結果をお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疫学

  • 背景
  • リスク要因と共存症
  • 世界の傾向
  • 予測手法
    • 利用した情報源
    • 利用しなかった情報源
    • 予測前提条件
  • 疫学的予測(今後10年間分)
    • 大腸癌の発症総件数
    • 特定の年齢層の大腸癌発症件数
    • 男女別の大腸癌発症件数
    • 年齢調整罹患率
    • 診断時の病期
    • 5年有病者数
    • 5年有病者数のKRAS ステータス
  • 議論

第4章 付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHCER006-14

Colorectal cancer (CRC) is cancer that starts in the colon or the rectum. CRC has the third highest incidence among all cancers in men and second highest in women. CRC is a high mortality cancer, with mortality rates just behind lung, liver, and stomach cancers in men, and breast and lung cancers in women. Most cases of CRC start as small adenoma polyps in the inner lining of the colon or rectum. CRC screening aims to identify and remove polyps when they are small to prevent the polyps from changing into cancer and has been shown to be effective in reducing the mortality from CRC.

GlobalData epidemiologists forecast that the number of total diagnosed incident cases of CRC in the 8MM is expected to grow from 758,062 cases in 2013 to 1,016,937 cases in 2023 at a rate of 3.41% per year during the forecast period. The number of diagnosed prevalent cases in the 8MM is expected to increase by 34.1% over the next decade from 2,583,156 cases in 2013 to 3,464,998 cases in 2023.

GlobalData's forecast and analysis is supported by at least 10 years of historical data obtained from international cancer organizations, country-specific government sources, and peer-reviewed studies. The forecast of incident CRC cases were based on detailed age-specific and sex-specific trends in incidence in each of the 8MM. This forecast provides detailed case-segmentation of the CRC pool for each country by age, sex, stage at diagnosis; prevalent cases are further segmented by KRAS mutation status, thereby providing a comprehensive view of CRC epidemiology in 8MM. The forecast is driven by a thorough analysis of historical data and current events such as screening initiatives and by the projected population growth in each country. The forecast methodology was also consistent across all eight markets, thereby allowing for a meaningful comparison among them.

Scope

  • The colorectal cancer (CRC) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for CRC in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and China [urban]). In addition, the report also includes a 10-year epidemiological forecast for the diagnosed incident cases of CRC and diagnosed five-year prevalent cases in these markets from 2013-2023. The diagnosed incident cases of CRC are further segmented by age (20-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and =80 years), sex, stage at diagnosis, and KRAS mutation status.
  • The CRC epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global CRC market.
  • Quantify patient populations in the global CRC market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups, sex, stage at diagnosis, and KRAS mutation status that present the best opportunities for CRC therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. 8MM, Incidence Trends
    • 3.3.2. 8MM, Five-Year Relative Survival
    • 3.3.3. 8MM, Screening Programs for CRC
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast of CRC (2013-2023)
    • 3.5.1. Diagnosed Incident Cases of CRC
    • 3.5.2. Age-Specific Diagnosed Incident Cases of CRC
    • 3.5.3. Sex-Specific Diagnosed Incident Cases of CRC
    • 3.5.4. Age-Standardized Incidence
    • 3.5.5. Cancer Stage at Diagnosis
    • 3.5.6. Diagnosed Five-Year Prevalent Cases of CRC
    • 3.5.7. KRAS Status among Diagnosed Five-Year Prevalent Cases of CRC
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Acting Global Director of Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for CRC
  • Table 2: 8MM, Five-Year Relative Survival
  • Table 3: 8MM, Sources of CRC Incidence Data
  • Table 4: 8MM, Sources of CRC Diagnosed Five-Year Prevalent Cases Data
  • Table 5: 8MM, Sources of CRC Cancer Stage at Diagnosis Data
  • Table 6: 8MM, Diagnosed Incident Cases of CRC, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Table 7: 8MM, Age-Specific Diagnosed Incident Cases of CRC, Both Sexes, N, Row (%), 2013
  • Table 8: 8MM, Sex-Specific Diagnosed Incident Cases of CRC, Ages ≥20 Years, 2013
  • Table 9: 8MM, Diagnosed Five-Year Prevalent Cases of CRC, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Table 10: 8MM, KRAS Status among CRC Prevalent Cases, 2013

List of Figures

  • Figure 1: Historical Age-Adjusted CRC Incidence (Cases per 100,000 Population) in 8MM, Men, 1998-2007
  • Figure 2: Historical Age-Adjusted CRC Incidence (Cases per 100,000 Population), in 8MM, Women, 1998-2007
  • Figure 3: 8MM, Diagnosed Incident Cases of CRC, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Figure 4: 8MM, Age-Specific Diagnosed Incident Cases of CRC, Both Sexes, N, 2013
  • Figure 5: 8MM, Sex-Specific Diagnosed Incident Cases of CRC, Ages ≥20 Years, 2013
  • Figure 6: 8MM, Age-Standardized Incidence of CRC (Cases per 100,000 Population), Ages ≥20 Years, by Sex, 2013.
  • Figure 7: 8MM, Cancer Stage at Diagnosis Percentage Distribution, Ages ≥20 Years.
  • Figure 8: 8MM, Diagnosed Five-Year Prevalent Cases of CRC, Both Sexes, Ages ≥20 Years, N, 2013-2023
Back to Top